Cancer Clinical Trials
Clinical trials are studies designed to find new and better ways to treat patients with cancer. Through clinical trials, scientists and physicians at the University of Maryland Marlene and Stewart Greenebaum Cancer Center are breaking new ground in the development of cancer treatments. Access to clinical trials is an important advantage of receiving your radiation therapy at UM BWMC.
We offer patients access to some of the 125 clinical trials currently being conducted at UMGCC. In this way, our patients may be eligible for new treatments not yet commercially available elsewhere. If you may be eligible for participation in one of the trials that are currently available, your physician may discuss it with you at the time of your consultation. If you are interested in one of the trials that are available in our department after discussing it with your physician, a research associate assists in coordinating participation.
Clinical Trials Currently Available at UM BWMC:
NRG-CC001 - A Randomized, Phase III Trial Of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases.
GCC 1547 - Ultrasound-based bladder scanning for reproducibility of bladderfilling during abdominopelvic external beam radiotherapy.
RTOG 1304 (NSABP B-51) - A randomized phase III clinical trial evaluating post-mastectomy chest wall and regional Nodal XRT and post-lumpectomy Regional Nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy.
A011106 - Alternate approaches for clinical stage II or III estrogen receptor positive breast cancer neoadjuvant treatment (ALTERNATE) in post-menopausal women.
NRG-BR002 - A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer.
A011401 - Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
A011502 - A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
A021502 - Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair.
GCC 1122 - “Observational study of hepatic metastasis of colorectal origin. International survey METSURVEY.” This study is offered by the Medical Director of the Tate Cancer Center, Cherif Boutros, MD, MSc, FACS. To find out more, please contact McKenzie Bedra, MPH at 410-553-8146 or McKenzie.Bedra@umm.edu.
GCC 1301 - “Postoperative heme oxygenase induction and carbon monoxide production as a novel method to assess hepatic regeneration and predict hepatic related morbidity after partial hepatectomy.” This study is offered by the Medical Director of the Tate Cancer Center, Cherif Boutros, MD, MSc, FACS. To find out more, please contact McKenzie Bedra, MPH at 410-553-8146 or McKenzie.Bedra@umm.edu.
NRG-CC003 - A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer.
NCT Clinical Trial 02041936 - “Outcomes of ablation of unresectable pancreatic cancer using the NanoKnife Irreversible Electroporation (IRE) System.” This study is offered by the Medical Director of the Tate Cancer Center, Cherif Boutros, MD. To find out more, please contact McKenzie Bedra, MPH at 410-553-8146 or McKenzie.Bedra@umm.edu.
HP 00067132 - “Assessing the significance of Platelet to Lymphocyte Ratio (PLR) as a simple, non-invasive marker of immunological response in pancreatic cancer and its association with tumor infiltrated T cells.” This study is offered by the Medical Director of the Tate Cancer Center, Cherif Boutros, MD. To find out more, please contact McKenzie Bedra, MPH at 410-553-8146 or McKenzie.Bedra@umm.edu.
HP 00073092 - A Prospective Quality of Life Study in Metastatic Pancreatic Cancer.
RTOG 0848 - A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.Watch surgical oncologist Cherif Boutros, MD, MSc, FACS, medical director of the Tate Cancer Center, chief of surgical oncology at UM BWMC and associate professor of surgery at the University of Maryland School of Medicine discuss the latest clinical trials for pancreatic cancer.
RTOG 0924 - Androgen deprivation therapy and high dose radiotherapy with or without whole- pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: A phase III randomized trial.
NRG-GU002 - Phase II-III Trial Of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or without Adjuvant Docetaxel.
GCC 1738 - PARTIQoL (Prostate Advanced Radiation Technologies Investigating Quality of Life) A Companion to Phase III Randomized PARTIQoL Clinical Trial.
NRG GU003 - A Randomized Phase III Trial of Hypofractionated Postprostatectomy Radiation Therapy (HYPORT) versus Conventional Post-prostatectomy Radiation Therapy (COPORT).
N1048 - A phase II/III trial of neoadjuvant FOLFOX, with selective use of combination modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision.